Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials  by Bilton, D. et al.
Journal of Cystic Fibrosis Volume 10 Suppl 2 (2011) S79–S81
www.elsevier.com/locate/jcf
Pulmonary exacerbation: Towards a deﬁnition for use in clinical trials.
Report from the EuroCareCF Working Group on outcome parameters in
clinical trials
D. Biltona,*, G. Cannyb, S. Conwayc, S. Dumciusd, L. Hjelte e, M. Proesmans f,
B. Tümmlerg, V. Vavrovah, K. De Boeck f
a Royal Brompton Hospital, London, UK
b Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland
c St. James’ Hospital, LS9 7TF, Leeds, UK
d Vilnius University, 08661, Vilnius, Lithuania
e Karolinska, Stockholm CF Centre, Huddinge, 14186 Stockholm, Sweden
f University Hospital Leuven, 3000 Leuven, Belgium
g Medizinische Hochschule Hannover, 30625 Hannover, Germany
h University Hospital Motol, Prague, 150 06 Prague 5, Czech Republic
Abstract
Pulmonary exacerbations represent a key outcome variable in clinical trials of cystic ﬁbrosis (CF). As there is variation in the trigger for
use of intravenous antibiotics compared to the use of oral antibiotics or new nebulised therapy for treatment of exacerbations, the consensus
view is that use of intravenous antibiotics cannot be regarded as the key deﬁning character for an exacerbation on its own. The consensus
view is that the clinical need for additional treatment as indicated by a recent change in clinical parameters provides the best deﬁnition of an
exacerbation. Which parameters to include as well as the problems associated with the use of scoring systems and symptom clusters are being
discussed.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Pulmonary exacerbations are a key outcome measure in
clinical trials because:
i Pulmonary exacerbations exhibit a strong contribution in a
well validated survivorship model. Each acute pulmonary
exacerbation had a negative impact on 5 year survival
equal to subtracting 12% of FEV1 [1]
ii Pulmonary exacerbations have been shown to have a
profound negative impact on health related quality of life
[2]
iii Pulmonary exacerbations have been a key secondary
endpoint in landmark studies of new therapies for cystic
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ﬁbrosis (CF), including RhDNase [3], Tobramycin (TOBI)
[4], Azithromycin [5] and hypertonic saline [6]
iv There are signiﬁcant costs associated with the requirement
for intravenous antibiotic therapy at home or in hospital
v As a result of i–iv above, reduction in pulmonary exacerba-
tions can be considered an important endpoint independent
of change in lung function.
There is consensus that pulmonary exacerbations represent
a key outcome variable in clinical trials of CF.
2. Deﬁnition of pulmonary exacerbation
2.1. Physician deﬁned requirement to treat
The simplest deﬁnition of pulmonary exacerbation is a
physician deﬁned requirement to intervene with new antibiotic
therapy, either oral or intravenous. This deﬁnition is open to
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variability depending on clinician preference and threshold
for treatment. However, this simple deﬁnition was used
effectively in the Azithromycin study [5] when exacerbations
were deﬁned as the use of intravenous anti-Pseudomonal
antibiotics or oral quinolones for seven or more days.
In the TOBI trial [4], use of intravenous antibiotics and
hospitalisation were used to characterise exacerbations and
revealed signiﬁcant beneﬁt in favour of the active treatment.
This deﬁnition is not recommended as a EuroCareCF
consensus as there may be variation in the prescription of
intravenous antibiotics and access to inpatient treatment in
different countries.
As there is variation in the trigger for use of intravenous
antibiotics compared to the use of oral antibiotics or new neb-
ulised therapy for treatment of exacerbations, the consensus
view is that use of intravenous antibiotics cannot be regarded
as the key deﬁning character for an exacerbation on its own.
2.2. Symptom deﬁned requirement to treat
Exacerbations can be usefully deﬁned by a cluster of
symptoms and signs as deﬁned by Fuchs et al. [3].
Clinical need for intravenous antibiotics as indicated by
presence of at least 4 of 12 possible signs or symptoms:
• Change in sputum volume or colour
• New or increased haemoptysis
• Increased cough
• Increased dyspnoea
• Increased malaise, fatigue or lethargy
• Temperature over 38°C
• Anorexia or weight loss
• Sinus pain or tenderness
• Change in sinus discharge
• Change in physical ﬁndings on examination of the chest
• Decrease in pulmonary function by 10% or more
• Radiographic changes
This deﬁnition has proven useful in the landmark DNase
study [3] and the large trial of hypertonic saline [6].
The criteria of Fuchs et al. [3] i.e.: symptom deﬁned (4 out
of 12) can be applied regardless of treatment. It is clear from
the hypertonic saline study that there is a signiﬁcant difference
in exacerbations deﬁned as per the original criteria of Fuchs
et al. [3] and an analysis involving symptoms identiﬁed by
Fuchs et al. [3] (hereafter termed Fuchs symptoms) regardless
of treatment.
The Fuchs symptoms deﬁned exacerbation with or without
requirement for treatment have shown utility in clinical trials
for both children and adults with CF. We recommend that this
deﬁnition is adopted for future clinical trials in Europe.
The consensus view is that the clinical need for additional
treatment as indicated by a recent change in clinical pa-
rameters provides the best deﬁnition of an exacerbation. The
clinical parameters used should be those of the criteria of
Fuchs et al. [3].
The European Consensus Group wishes to validate modi-
ﬁed criteria of Fuchs et al. [3] as follows:
An exacerbation will be deﬁned as the need for additional
antibiotic treatment as indicated by a recent change in at least
two of the following:
• Change in sputum volume or colour
• Increased cough
• Increased malaise, fatigue or lethargy
• Anorexia or weight loss
• Decrease in pulmonary function by 10% or more /
Radiographic changes
• Increased dyspnoea
2.3. Scoring system to deﬁne exacerbation
Several studies have addressed the possibility of standard-
ising a symptom deﬁned exacerbation score. However, these
are subject to the difﬁculty of deciding on the gold standard
for validation. If the gold standard is the physician’s opinion
then variability is likely to be introduced. An Australian
survey highlighted this problem [7]. Rosenfeld et al. [8]
developed two scores which were validated in the intervention
arm of the TOBI trial. One score included lung function as
a variable. The second had no requirement for lung function.
The utility of this is obvious in terms of pan-European studies
and the algorithm produces a score where the critical value of
2.6 or above represents a physician deﬁned exacerbation. The
problem with this score is that it does not necessarily correlate
with a new treatment or intervention.
2.4. Symptom cluster that deﬁnes need for treatment
Rabin et al. [9] examined patient registry data in order to
predict the factors that were associated with new treatment.
The scoring system developed by Rabin et al. [9] deﬁnes
separate criteria for different age groups and in particular
includes a deﬁnition of exacerbations for under 6 year olds.
The scoring system of Rabin et al. [9] appears easy to apply
in clinical studies, but does not have a track record in clinical
trials.
The consensus view is that the scoring system of Rosenfeld
et al. [8] should not be used for European studies as the
deﬁning score does not always correlate with a change in
treatment. The scoring system developed by Rabin et al. [9]
could be used, but because it has no track record in clinical
trials we do not recommend it for current use. Future trials
could incorporate a validation of the scoring system of Rabin
et al. [9] particularly in studies of children under 6 years of
age.
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